Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Mefloquine · 2 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| 2 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Azithromycin plus Chloroquine | DRUG | Azithromycin 1000 mg by mouth (PO) (two 500 mg tablets) once daily (QD) for 3 days(Days 0, 1, 2) plus chloroquine 600 mg base PO once daily for 3 days (Days 0, 1, 2) |
| Mefloquine | DRUG | Mefloquine 1250 mg PO given as a split dose (750 mg \[three 250 mg capsules\]) initial dose followed by 500 mg PO (two 250 mg capsules) given 6 to 10 hours later on Day 0 |
| Azithromycin/Chloroquine | DRUG | - |
Inclusion Criteria: * Females and males 18 years of age and older with uncomplicated, symptomatic malaria as as indicated by the presence of both of the following: * Blood smears positive for Plasmodium falciparum asexual parasitemia between 1000 -100,000 parasites * Documented fever (38.5 C/101.3 ...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GSK plc Sponsored ADR | GSK | 3 | PHASE3 | Tafenoquine, Primaquine, Chloroquine |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE2 | INE963, KAE609, KLU156 |
| 60 Degrees Pharmaceuticals, Inc. | SXTP | 1 | PHASE2 | Tafenoquine |
Mefloquine is used for the treatment of uncomplicated malaria, including falciparum malaria. It is being studied in clinical trials for this infectious disease indication. The drug is administered to adult patients, and trials have been conducted in multiple African countries where malaria is prevalent.
Mefloquine is being developed by Pfizer, Inc., a pharmaceutical company traded on the New York Stock Exchange under the ticker symbol PFE. Pfizer is conducting clinical trials to evaluate the drug for the treatment of uncomplicated malaria in adult patients.
Mefloquine is in Phase 3 clinical development for the treatment of uncomplicated malaria. It has completed a Phase 3 trial with 397 participants. The drug is investigational and has not been approved for this use, as it is still undergoing clinical evaluation.
Mefloquine has been studied in two completed clinical trials. One trial, NCT00082576, was a Phase 2 study comparing azithromycin plus chloroquine versus mefloquine in 238 patients with falciparum malaria. Another trial, NCT00367653, was a Phase 3 study in 397 patients with uncomplicated malaria.
Mefloquine is the generic name for the drug also known as Lariam. In clinical trials, it is referred to as mefloquine, and it is being evaluated for the treatment of uncomplicated malaria. The drug is a small molecule developed by Pfizer.